NRx Pharmaceuticals, Inc.(NRXP)Earnings, Financials & Key Ratios
NRXP•NASDAQ
$3.05
$84M mkt cap·Price updated May 6, 2026
AboutNRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.Show more
- Revenue$1M
- EBITDA-$16M+18.0%
- Net Income-$29M-13.9%
- EPS (Diluted)-1.34+43.9%
- EBITDA Margin-1318.69%
- Operating Margin-1324.41%
- Net Margin-2336.49%
- Interest Coverage-24.18-32.4%
NRXP Key Insights
NRx Pharmaceuticals, Inc. (NRXP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NRXP Price & Volume
NRx Pharmaceuticals, Inc. (NRXP) stock price & volume — 10-year historical chart
Loading chart...
NRXP Growth Metrics
NRx Pharmaceuticals, Inc. (NRXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-86.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-44.83%
Return on Capital
10 Years-186.53%
5 Years-371.63%
3 Years-
Last Year-
NRXP Peer Comparison
NRx Pharmaceuticals, Inc. (NRXP) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 ALTO | 429.75M | 5.56 | 34.75 | -4.9% | 1.45% | 6% | 0.40 | |
 INMB | 40.41M | 1.52 | -0.72 | -90.97% | -997.74% | -172% | 0.01 | |
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 NRXS | 93.85M | 8.81 | -9.27 | 32.89% | -218.55% | -306.02% | 0.06 | |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 0.78 |
Compare NRXP vs Peers
NRx Pharmaceuticals, Inc. (NRXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRXP Income Statement
NRx Pharmaceuticals, Inc. (NRXP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.23M | 242K |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 1.01M | 0 | 2K | 2K | 4K | 5K | 5K | 0 | 98K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -1.01M▲ 0% | 0▲ 100.0% | -2K▲ 0% | -2K▲ 0.0% | -4K▼ 100.0% | -5K▼ 25.0% | -5K▲ 0.0% | 0▲ 100.0% | 144K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | 59.5% |
| Gross Profit Growth % | - | - | 100% | - | 0% | -100% | -25% | 0% | 100% | - |
| Operating Expenses | 0 | 0 | 713.19K | 22.06M | 95.2M | 44.33M | 27.58M | 19.7M | 17.45M | 15.38M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 1424.41% | - |
| Selling, General & Admin | 0 | 1.01M | 713.19K | 11.43M | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M | 11.09M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 1066.2% | - |
| Research & Development | 0 | 0 | 0 | 10.63M | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M | 4.26M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 308.33% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 611K | 32K |
| Operating Income | 0▲ 0% | -1.01M▲ 0% | -713.19K▲ 29.1% | -22.06M▼ 2993.3% | -95.2M▼ 331.5% | -44.34M▲ 53.4% | -27.59M▲ 37.8% | -19.7M▲ 28.6% | -16.22M▲ 17.7% | -15.23M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | -1324.41% | -6295.45% |
| Operating Income Growth % | - | - | 29.14% | -2993.3% | -331.54% | 53.43% | 37.78% | 28.58% | 17.66% | - |
| EBITDA | -105K | 82.41K | 492.63K | -22.06M | -95.2M | -44.33M | -27.58M | -19.7M | -16.15M | -30.71M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -1318.69% | -12688.84% |
| EBITDA Growth % | - | 178.49% | 497.77% | -4577.78% | -331.57% | 53.43% | 37.78% | 28.58% | 18% | -50% |
| D&A (Non-Cash Add-back) | 52.52K | 0 | 0 | 2K | 2K | 4K | 5K | 5K | 70K | 44K |
| EBIT | -105K | 82.41K | 492.63K | -51.72M | -93.05M | -39.75M | -30.03M | -24.05M | 0 | -38.06M |
| Net Interest Income | 0 | 0 | 1.21M | -55.94K | -17.98K | 249K | 374K | -1.03M | 0 | 12K |
| Interest Income | 0 | 1.09M | 1.21M | 56 | 18 | 249K | 494K | 44K | -12K | 12K |
| Interest Expense | 0 | 0 | 0 | 56K | 18K | 0 | 120K | 1.08M | 671K | 0 |
| Other Income/Expense | -105K | 1.09M | 1.21M | -29.72M | 2.14M | 4.58M | -2.56M | -5.42M | -12.4M | -22.83M |
| Pretax Income | -105K▲ 0% | 82.41K▲ 178.5% | 492.63K▲ 497.8% | -51.78M▼ 10610.3% | -93.06M▼ 79.7% | -39.75M▲ 57.3% | -30.15M▲ 24.2% | -25.13M▲ 16.7% | -28.62M▼ 13.9% | -38.06M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | -2336.49% | -15727.69% |
| Income Tax | 0 | 16.31K | 84.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 19.79% | 17.09% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -105K▲ 0% | 66.1K▲ 163.0% | 408.43K▲ 517.9% | -51.78M▼ 12777.2% | -93.06M▼ 79.7% | -39.75M▲ 57.3% | -30.15M▲ 24.2% | -25.13M▲ 16.7% | -28.62M▼ 13.9% | -38.06M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | -2336.49% | -15727.69% |
| Net Income Growth % | - | 162.95% | 517.88% | -12777.17% | -79.74% | 57.28% | 24.16% | 16.66% | -13.91% | -86.76% |
| Net Income (Continuing) | -105K | 66.1K | 408.43K | -51.78M | -93.06M | -39.75M | -30.15M | -25.13M | -28.62M | -38.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.12▲ 0% | 0.07▲ 161.8% | 0.80▲ 979.6% | -1.51▼ 288.8% | -7.44▼ 392.7% | -0.60▲ 91.9% | -3.98▼ 563.3% | -2.39▲ 39.9% | -1.34▲ 43.9% | -1.71▲ 0% |
| EPS Growth % | - | 161.75% | 979.62% | -288.75% | -392.72% | 91.94% | -563.33% | 39.95% | 43.93% | -44.83% |
| EPS (Basic) | -0.12 | 0.07 | 0.80 | -1.51 | -7.44 | -0.60 | -3.98 | -2.39 | -1.34 | - |
| Diluted Shares Outstanding | 903.55K | 892.5K | 508.83K | 546.59K | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M | 22.23M |
| Basic Shares Outstanding | 903.55K | 892.5K | 508.83K | 546.59K | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M | 22.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NRXP Balance Sheet
NRx Pharmaceuticals, Inc. (NRXP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 536.38K | 30.19K | 69.49K | 2.93M | 32.71M | 25.8M | 6.88M | 3.3M | 8.89M | 11.95M |
| Cash & Short-Term Investments | 449.37K | 11.08K | 6 | 1.86M | 27.61M | 20.05M | 4.59M | 1.44M | 7.8M | 7.18M |
| Cash Only | 449.37K | 11.08K | 6 | 1.86M | 27.61M | 20.05M | 4.59M | 1.44M | 7.8M | 7.18M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 831K | 0 | 7K | 6K | 0 | 161K | 239K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | 47.97 | 90.12 |
| Inventory | 0 | 0 | 0 | 214K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | 39.05K | - | - | - | - | - | - |
| Other Current Assets | 87K | 19.11K | 0 | 26K | 0 | 0 | 0 | 0 | 934K | 4.52M |
| Total Non-Current Assets | 69.03M | 70.77M | 32.01M | 11K | 15K | 21K | 431K | 349K | 4.06M | 3.05M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 633K | 350K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | 1.94x | 2.77x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.79M | 610K |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 925K | 1.78M |
| Long-Term Investments | 69.03M | 70.77M | 32.01M | 0 | 0 | 0 | 0 | 0 | 397K | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 11K | 15K | 21K | 431K | 349K | 316K | 1.24M |
| Total Assets | 69.57M▲ 0% | 70.8M▲ 1.8% | 32.07M▼ 54.7% | 2.94M▼ 90.8% | 32.73M▲ 1012.9% | 25.82M▼ 21.1% | 7.32M▼ 71.7% | 3.65M▼ 50.1% | 12.96M▲ 254.9% | 15M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | 0.09x | 0.03x |
| Asset Growth % | - | 1.77% | -54.69% | -90.83% | 1012.85% | -21.12% | -71.66% | -50.09% | 254.86% | 278.27% |
| Total Current Liabilities | 93.17K | 567.41K | 622.44K | 46.16M | 11.92M | 15.59M | 19.05M | 21.86M | 28.58M | 40.59M |
| Accounts Payable | 85.67K | 551.1K | 0 | 3.15M | 3.69M | 2.08M | 4.63M | 4.13M | 4.27M | 4.26M |
| Days Payables Outstanding | - | 199.85 | - | 575.42K | 672.88K | 189.44K | 338.14K | 301.49K | - | 15.2K |
| Short-Term Debt | 0 | 0 | 0 | 249K | 518K | 7.7M | 9.16M | 1.57M | 316K | 189K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.5K | 0 | 622.44K | 0 | 4.87M | 37K | 4.42M | 10.93M | 28.26M | 36.15M |
| Current Ratio | 5.76x | 0.05x | 0.11x | 0.06x | 2.74x | 1.66x | 0.36x | 0.15x | 0.31x | 0.31x |
| Quick Ratio | 5.76x | 0.05x | 0.11x | 0.06x | 2.74x | 1.66x | 0.36x | 0.15x | 0.31x | 0.31x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -15.11K |
| Total Non-Current Liabilities | 0 | 690K | 1.95M | 548K | 0 | 2.82M | 0 | 5.01M | 315K | 158K |
| Long-Term Debt | 0 | 690K | 1.95M | 548K | 0 | 2.82M | 0 | 5.01M | 315K | 158K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 93.17K | 1.26M | 2.57M | 46.71M | 11.92M | 18.41M | 19.05M | 26.87M | 28.89M | 40.75M |
| Total Debt | 0 | 690K | 1.95M | 797K | 518K | 10.53M | 9.16M | 6.58M | 631K | 347K |
| Net Debt | -449.37K | 678.92K | 1.95M | -1.06M | -27.09M | -9.53M | 4.57M | 5.13M | -7.17M | -6.84M |
| Debt / Equity | - | 0.01x | 0.07x | - | 0.02x | 1.42x | - | - | - | -0.01x |
| Debt / EBITDA | - | 8.37x | 3.96x | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | 8.24x | 3.96x | - | - | - | - | - | - | 0.22x |
| Interest Coverage | - | - | - | -393.95x | -5288.94x | - | -229.89x | -18.26x | -24.18x | - |
| Total Equity | 69.47M▲ 0% | 69.54M▲ 0.1% | 29.5M▼ 57.6% | -43.77M▼ 248.4% | 20.81M▲ 147.5% | 7.41M▼ 64.4% | -11.73M▼ 258.4% | -23.22M▼ 97.9% | -15.94M▲ 31.4% | -25.75M▲ 0% |
| Equity Growth % | - | 0.1% | -57.58% | -248.37% | 147.53% | -64.39% | -258.36% | -97.93% | 31.37% | -295.39% |
| Book Value per Share | 76.89 | 77.91 | 57.98 | -80.08 | 0.44 | 0.11 | -1.55 | -2.21 | -0.74 | -1.16 |
| Total Shareholders' Equity | 69.47M | 69.54M | 29.5M | -43.77M | 20.81M | 7.41M | -11.73M | -23.22M | -15.94M | -25.75M |
| Common Stock | 64.48M | 64.54M | 24.5M | 43K | 59K | 67K | 84K | 15K | 32K | 28K |
| Retained Earnings | -105.03K | -38.93K | 369.5K | -90.18M | -183.24M | -223M | -253.15M | -278.27M | -306.89M | -307.26M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -3K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRXP Cash Flow Statement
NRx Pharmaceuticals, Inc. (NRXP) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -135.81K | -473.19K | -792.73K | -2.27M | -37.7M | -39.76M | -21.66M | -10.64M | -14.11M | -14.11M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | -1152% | - |
| Operating CF Growth % | - | -248.43% | -67.53% | -185.72% | -1564.59% | -5.44% | 45.52% | 50.88% | -32.67% | 19.05% |
| Net Income | -105.03K | 66.1K | 408.43K | -51.78M | -93.06M | -39.75M | -30.15M | -25.13M | -28.62M | -38.06M |
| Depreciation & Amortization | 0 | 0 | 0 | 2K | 2K | 4K | 5K | 5K | 143K | 42K |
| Stock-Based Compensation | 0 | 0 | 0 | 730K | 7.79M | 3.63M | 387K | 486K | 228K | 122K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -115.11K | -1.55M | -1.21M | 45.33M | 52.47M | -4.33M | 2.94M | 8.71M | 14.14M | 25.43M |
| Working Capital Changes | -1.33K | 549.63K | 4.66K | 3.45M | -4.9M | 699K | 5.16M | 5.29M | 0 | 599K |
| Change in Receivables | 0 | 0 | 0 | -831K | 831K | 0 | 0 | 0 | 48K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 85.67K | 465.43K | 0 | 1.18M | -19K | -1.61M | 2.65M | -5.22M | 113K | 100K |
| Cash from Investing | -69M | -647.61K | 40.25M | -2K | -7K | -10K | -3K | 0 | -2.81M | -2.56M |
| Capital Expenditures | 0 | 0 | 0 | -2K | -7K | -10K | -3K | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.38M | -2.56M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -69M | -647.61K | 0 | 0 | 0 | 0 | 0 | 0 | -432K | 0 |
| Cash from Financing | 69.59M | 682.5K | -39.46M | 3.25M | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M | 19.96M |
| Debt Issued (Net) | 0 | 690K | 1.26M | 620K | -1.28M | 9.5M | -3.09M | -1.5M | 0 | 8.15M |
| Equity Issued (Net) | 69.59M | -7.5K | -40.73M | 2.63M | 36.98M | 22.7M | 9.29M | 5.91M | 0 | 12.16M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 70.03M | 0 | -40.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 27.75M | 10K | 0 | 3.07M | 23.28M | -351K |
| Net Change in Cash | 449.37K▲ 0% | -438.3K▼ 197.5% | -11.07K▲ 97.5% | 982K▲ 8968.4% | 25.75M▲ 2521.8% | -7.55M▼ 129.3% | -15.46M▼ 104.7% | -3.15M▲ 79.6% | 6.35M▲ 301.6% | 5.54M▲ 0% |
| Free Cash Flow | -135.81K▲ 0% | -473.19K▼ 248.4% | -792.73K▼ 67.5% | -2.27M▼ 186.0% | -37.71M▼ 1563.4% | -39.77M▼ 5.4% | -21.66M▲ 45.5% | -10.64M▲ 50.9% | -14.11M▼ 32.7% | -11.86M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | -1152% | -4902.07% |
| FCF Growth % | - | -248.43% | -67.53% | -185.97% | -1563.43% | -5.45% | 45.53% | 50.89% | -32.67% | 6.39% |
| FCF per Share | -0.15 | -0.53 | -1.56 | -4.15 | -0.80 | -0.60 | -2.86 | -1.01 | -0.66 | -0.66 |
| FCF Conversion (FCF/Net Income) | 1.29x | -7.16x | -1.94x | 0.04x | 0.41x | 1.00x | 0.72x | 0.42x | 0.49x | 0.31x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 885K | 374K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRXP Key Ratios
NRx Pharmaceuticals, Inc. (NRXP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 0.1% | 0.82% | - | -447.29% | -281.79% | - | - | - | 138.71% |
| Return on Invested Capital (ROIC) | -1.08% | -1.05% | - | - | - | - | - | - | 45.12% |
| Gross Margin | - | - | - | - | - | - | - | - | 59.5% |
| Net Margin | - | - | - | - | - | - | - | -2336.49% | -15727.69% |
| Debt / Equity | 0.01x | 0.07x | - | 0.02x | 1.42x | - | - | - | -0.01x |
| Interest Coverage | - | - | -393.95x | -5288.94x | - | -229.89x | -18.26x | -24.18x | - |
| FCF Conversion | -7.16x | -1.94x | 0.04x | 0.41x | 1.00x | 0.72x | 0.42x | 0.49x | 0.31x |
NRXP Frequently Asked Questions
NRx Pharmaceuticals, Inc. (NRXP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NRx Pharmaceuticals, Inc. (NRXP) reported $0.2M in revenue for fiscal year 2025.
NRx Pharmaceuticals, Inc. (NRXP) grew revenue by 0.0% over the past year. Growth has been modest.
NRx Pharmaceuticals, Inc. (NRXP) reported a net loss of $38.1M for fiscal year 2025.
Dividend & Returns
NRx Pharmaceuticals, Inc. (NRXP) had negative free cash flow of $11.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More NRXP
NRx Pharmaceuticals, Inc. (NRXP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates